Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis

Project Details

StatusActive
Effective start/end date24/05/2129/12/23

Funding

  • Avalyn Pharma: A$10,000.00
  • Avalyn Pharma: A$30,000.00
  • Avalyn Pharma: A$10,954.00
  • Avalyn Pharma: A$18,187.00